386 results on '"Sande, Marleen"'
Search Results
2. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
3. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
4. 18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients
5. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
6. Pathophysiology and immunolgical basis of axial spondyloarthritis
7. Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool
8. ASAS consensus definition of early axial spondyloarthritis.
9. P167 Bimekizumab achieved sustained improvements in efficacy outcomes in patients with axial spondyloarthritis, regardless of prior tumour necrosis factor inhibitor treatment: week 52 pooled results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
10. Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
11. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
12. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis:Results From the European Spondyloarthritis Research Collaboration Network
13. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor:results from 13 European registries
14. Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2- year SPondyloArthritis Caught Early (SPACE) cohort.
15. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
16. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network
17. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
18. HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort
19. Anti-IL-17A treatment reduces serum inflammatory, angiogenic and tissue remodeling biomarkers accompanied by less synovial high endothelial venules in peripheral spondyloarthritis
20. ASAS consensus definition of early axial spondyloarthritis
21. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
22. Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis
23. Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target.
24. Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target
25. E089 Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial
26. OA18 Smoking and high BMI are associated with reductions in TNF inhibitor response in psoriatic arthritis: results from 12 European countries
27. EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders
28. Hyaluronic Acid in Synovial Fluid Prevents Neutrophil Activation in Spondyloarthritis
29. Hyaluronic Acid in Synovial Fluid Prevents Neutrophil Activation in Spondyloarthritis
30. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
31. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis:Results from the EuroSpA Research Collaboration Network
32. Hyaluronic Acid in Synovial Fluid Prevents Neutrophil Activation in Spondyloarthritis
33. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
34. Lower Metabolic Potential and Impaired Metabolic Flexibility in Human Lymph Node Stromal Cells from Patients with Rheumatoid Arthritis
35. Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial
36. Synovial gene signatures associated with the development of rheumatoid arthritis in at risk individuals: A prospective study
37. 18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients
38. Additional file 1 of Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
39. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries
40. Progression From Subclinical Inflammation to Overt Spondyloarthritis (SpA) in First-Degree Relatives of SpA Patients in Association With HLA-B27: the Pre-SpA cohort
41. Correction: HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort
42. Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort
43. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort
44. New treatment paradigms in spondyloarthritis
45. Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
46. Su1746 SPHINGOSINE-1-PHOSPHATE RECEPTOR BLOCKADE WITH ETRASIMOD ALTERS LYMPHOCYTE TRAFFICKING IN CROHN'S DISEASE: INSIGHTS FROM HIGH-DIMENSIONAL PHENOTYPIC MAPPING
47. Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
48. European bio-naïve spondyloarthritis patients initiating TNF inhibitor:time trends in baseline characteristics, treatment retention and response
49. Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial.
50. 18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.